MedTrace Logo

A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954

NCT06937593 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-08-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of VIS954 compared with placebo in healthy adult participants.

Conditions

  • Healthy

Interventions

DRUG

VIS954

A humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)

DRUG

Placebo

VIS954 Placebo

Sponsors & Collaborators

  • Visterra, Inc.

    lead INDUSTRY

Principal Investigators

  • Peter J Winkle, MD · Anaheim Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2026-01-06
Completion
2026-02-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06937593 on ClinicalTrials.gov